---
title: "Ivonescimab in EGFR-mutated non-small-cell lung cancer: References"
description: "Reference list for the formulary evidence report on Ivonescimab in EGFR-mutated non-small-cell lung cancer. 73 cited documents."
canonical: "https://www.evicenter.com/drugs/ivonescimab--egfr-mutated-non-small-cell-lung-cancer/references"
published: "2026-09-14T15:39:06-04:00"
modified: "2026-11-17T19:46:23-05:00"
---

# Ivonescimab in EGFR-mutated non-small-cell lung cancer: References

<a id="references"></a>

## 5 References

1. [Akeso (2026)](https://www.prnewswire.com/news-releases/ivonescimab-receives-major-recommendations-across-multiple-therapies-in-the-2026-csco-nsclc-guideline-302755438.html)
2. [Akeso ivonescimab package insert](https://akesobio.com/media/2634/%E4%BE%9D%E6%B2%83%E8%A5%BF%E5%8D%95%E6%8A%97%E6%B3%A8%E5%B0%84%E6%B6%B2-ak112-306-%E8%AF%B4%E6%98%8E%E4%B9%A6-cxss500077-20260811.pdf)
3. [Akeso ivonescimab product page](https://akesobio.com/en/rd-and-science/products-center/ivonescimab/)
4. [Al Matairi et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11818946/)
5. [CDC (2026)](https://www.cdc.gov/united-states-cancer-statistics/publications/lung-cancer-stat-bite.html)
6. [Chen et al. (2025)](https://journals.sagepub.com/doi/10.1177/17588359251405044)
7. [Cheng et al. (2025)](https://jamanetwork.com/journals/jama/fullarticle/2827784)
8. [Chiu et al. (2022)](https://journals.sagepub.com/doi/10.1177/23814683221113846)
9. [Dai et al. (2026)](https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2026.1770637/full)
10. [Dhillon (2024)](https://pubmed.ncbi.nlm.nih.gov/39073550/)
11. [Fang et al. (2025)](https://jamanetwork.com/journals/jama/fullarticle/2827782)
12. [FDA (2018)](https://www.fda.gov/media/71195/download)
13. [FDA (2024)](https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-amivantamab-vmjw-carboplatin-and-pemetrexed-non-small-cell-lung-cancer-egfr-exon-19)
14. [FDA (2025)](https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-datopotamab-deruxtecan-dlnk-egfr-mutated-non-small-cell-lung-cancer)
15. [Frentzas et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11033648/)
16. [HARMONi-A Study Investigators (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11337070/)
17. [HARMONi-A Study Investigators (2026)](https://pubmed.ncbi.nlm.nih.gov/42307937/)
18. [IASLC (2025)](https://www.iaslc.org/iaslc-news/press-release/ivonescimab-plus-chemotherapy-improves-progression-free-survival-patients)
19. [JAMA Research Summary (2026)](https://jamanetwork.com/journals/jama/fullarticle/2850532)
20. [Jing et al. (2026)](https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2026.1864144/full)
21. [Le et al. (2026a)](https://s206.q4cdn.com/652410165/files/doc_downloads/publications/2026/03/3-Intracranial-Efficacy-of-Ivonescimab-Plus-Chemotherapy-in-Epidermal-Growth-Factor-Receptor-EGFR-Tyrosine-Kinase-Inhibitor-Resistant-EGFR-Mu.pdf)
22. [Le et al. (2026b)](https://pubmed.ncbi.nlm.nih.gov/42636833/)
23. [Lee et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11648200/)
24. [Leighl et al. (2026)](https://www.esmoopen.com/article/S2059-7029%2826%2900269-3/fulltext)
25. [Liu et al. (2025)](https://jamanetwork.com/journals/jama/fullarticle/2827783)
26. [Long et al. (2025)](https://tlcr.amegroups.org/article/view/100492/html)
27. [Malapelle et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11886603/)
28. [MedlinePlus Genetics](https://medlineplus.gov/genetics/gene/egfr/)
29. [MedlinePlus lung cancer genetic tests](https://medlineplus.gov/lab-tests/lung-cancer-genetic-tests/)
30. [MedlinePlus non-small cell lung cancer](https://www.medlineplus.gov/ency/article/007194.htm)
31. [Mo et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12753922/)
32. [Mok et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11095864/)
33. [National Cancer Institute](https://www.cancer.gov/publications/dictionaries/cancer-drug/def/ivonescimab)
34. [National Cancer Institute (2021)](https://www.cancer.gov/about-cancer/advanced-cancer/care-choices/palliative-care-fact-sheet)
35. [National Medical Products Administration (2025)](https://english.nmpa.gov.cn/2025-02/19/c_1073557.htm)
36. [Pan et al. (2025)](https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2025.1707096/full)
37. [Pang et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/40081325/)
38. [Passaro et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/37879444/)
39. [Patel et al. (2026)](https://www.clinical-lung-cancer.com/article/S1525-7304%2826%2900028-8/fulltext)
40. [PDQ Adult Treatment Editorial Board (2025)](https://www.cancer.gov/types/lung/hp/non-small-cell-lung-treatment-pdq)
41. [Peled et al. (2025)](https://cris.bgu.ac.il/en/publications/compel-osimertinib-plus-platinum-based-chemotherapy-in-patients-w-2/)
42. [Sands et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11949215/)
43. [Summit Therapeutics Akeso partnership page](https://smmttx.com/ivonescimab-smt112/akeso-partnership/default.aspx)
44. [Summit Therapeutics BLA acceptance announcement (2026)](https://smmttx.com/news/press-releases/news-details/2026/Summit-Therapeutics-Announces-U-S--FDA-Acceptance-of-Biologics-License-Application-BLA-Seeking-Approval-for-Ivonescimab-in-Combination-with-Chemotherapy-in-Treatment-of-Patients-with-EGFRm-NSCLC-Post-TKI-Therapy/default.aspx)
45. [Summit Therapeutics BLA submission announcement (2026)](https://smmttx.com/news/press-releases/news-details/2026/Summit-Therapeutics-Announces-Submission-of-Biologics-License-Application-BLA-to-U-S--FDA-Seeking-Approval-for-Ivonescimab-in-Combination-with-Chemotherapy-in-2L-Treatment-of-Patients-with-EGFRm-NSCLC/default.aspx)
46. [Summit Therapeutics China NMPA approval announcement (2024)](https://www.prnewswire.com/news-releases/ivonescimab-in-combination-with-chemotherapy-approved-in-china-by-nmpa-for-2l-egfrm-nsclc-based-on-harmoni-a-clinical-trial-positive-trend-observed-in-overall-survival-towards-ivonescimab-plus-chemotherapy-302161109.html)
47. [Summit Therapeutics complete response letter announcement (2026)](https://smmttx.com/news/press-releases/news-details/2026/Summit-Therapeutics-Provides-Update-Regarding-Ivonescimab-Biologics-License-Application/default.aspx)
48. [Summit Therapeutics ELCC 2026 presentations announcement (2026)](https://smmttx.com/news/press-releases/news-details/2026/Multiple-Ivonescimab-Data-Sets-from-Phase-III-Studies-in-Advanced-NSCLC-Patient-Populations-to-be-Featured-at-ELCC-2026/default.aspx)
49. [Summit Therapeutics expanded access page](https://smmttx.com/clinical-trials/Expanded-Access/default.aspx)
50. [Summit Therapeutics Form 10-K (2025)](https://www.sec.gov/Archives/edgar/data/1599298/000159929825000048/smmt-20241231.htm)
51. [Summit Therapeutics Form 10-Q (2026)](https://www.sec.gov/Archives/edgar/data/1599298/000159929826000068/smmt-20260630.htm)
52. [Summit Therapeutics HARMONi enrollment completion announcement (2024)](https://smmttx.com/news/press-releases/news-details/2024/Summit-Therapeutics-Announces-Completion-of-Enrollment-in-Its-Phase-III-HARMONi-Trial-in-2L-EGFRm-NSCLC-10-03-2024-12-00-AM/default.aspx)
53. [Summit Therapeutics HARMONi enrollment fact sheet (2025)](https://s206.q4cdn.com/652410165/files/doc_downloads/fact-sheets/MAT-SMT112-0070_-HARMONi-Patient-Enrollment-2-pager-Public-April2025-2.pdf)
54. [Summit Therapeutics HARMONi longer-term follow-up announcement (2025)](https://smmttx.com/news/press-releases/news-details/2025/Longer-Term-Follow-Up-of-Western-Patients-Showed-Improving-Favorable-Trend-in-Overall-Survival-in-Global-Phase-III-HARMONi-Clinical-Trial-for-Ivonescimab-Plus-Chemotherapy-in-2L-EGFRm-NSCLC/default.aspx)
55. [Summit Therapeutics HARMONi progression-free survival announcement (2025)](https://smmttx.com/news/press-releases/news-details/2025/Ivonescimab-Plus-Chemotherapy-Demonstrates-Statistically-Significant-and-Clinically-Meaningful-Improvement-in-Progression-Free-Survival-in-Patients-with-EGFR-Mutant-Non-Small-Cell-Lung-Cancer-after-EGFR-TKI-Therapy-in-Global-Study/default.aspx)
56. [Summit Therapeutics HARMONi trial page](https://smmttx.com/clinical-trials/harmoni-clinical-trial/default.aspx)
57. [Summit Therapeutics HARMONi updated overall survival announcement (2026)](https://smmttx.com/news/press-releases/news-details/2026/Ivonescimab-Plus-Chemotherapy-Shows-Consistent-Favorable-Overall-Survival-Results-in-Western-and-Asian-Patients-in-Updated-Analysis-from-Global-Phase-III-HARMONi-Study/default.aspx)
58. [Summit Therapeutics HARMONi-A overall survival announcement (2025)](https://www.smmttx.com/news/press-releases/news-details/2025/Ivonescimab-Plus-Chemotherapy-Demonstrates-a-Statistically-Significant-Benefit-in-Overall-Survival-with-a-Hazard-Ratio-of-0-74-in-2L-Treatment-of-Patients-with-EGFRm-NSCLC-in-HARMONi-A-Study-Conducted-by-Akeso-in-China/default.aspx)
59. [Summit Therapeutics ivonescimab overview page](https://smmttx.com/ivonescimab-smt112/ivonescimab-overview/default.aspx)
60. [Sun et al. (2026)](https://www.ispor.org/heor-resources/presentations-database/presentation-cti/ispor-2026/poster-session-2-4/cost-effectiveness-analysis-of-savolitinib-osimertinib-in-advanced-non-squamous-nsclc-with-met-amplification-following-egfr-tki-resistance-in-china)
61. [Vanderpoel et al. (2023)](https://link.springer.com/article/10.1007/s41669-023-00407-0)
62. [Vyas et al. (2026)](https://link.springer.com/article/10.1007/s11912-026-01751-0)
63. [Wang et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/37879536/)
64. [Wang et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11925807/)
65. [Waterhouse et al. (2025)](https://jheor.org/article/142771-healthcare-resource-use-healthcare-costs-and-unmet-needs-among-patients-treated-for-egfr-mutated-advanced-or-metastatic-non-small-cell-lung-cancer)
66. [Yang et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11608596/)
67. [Yang et al. (2025)](https://www.annalsofoncology.org/article/S0923-7534%2825%2905755-2/fulltext)
68. [Yang et al. (2026)](https://www.asco.org/abstracts-presentations/265972)
69. [Zhang et al. (2025)](https://journals.sagepub.com/doi/10.1177/17588359251338046)
70. [Zhao et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10430160/)
71. [Zhong et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11872405/)
72. [Zhou et al. (2026)](https://www.dovepress.com/ivonescimab-plus-chemotherapy-versus-bevacizumab-plus-chemotherapy-in--peer-reviewed-fulltext-article-DDDT)
73. [Zhu et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13220079/)

## Related pages
- [Ivonescimab: EGFR-mutated non-small-cell lung cancer](https://www.evicenter.com/drugs/ivonescimab--egfr-mutated-non-small-cell-lung-cancer) · [Markdown](https://www.evicenter.com/drugs/ivonescimab--egfr-mutated-non-small-cell-lung-cancer.md)
- [Ivonescimab in EGFR-mutated non-small-cell lung cancer: Terms and abbreviations](https://www.evicenter.com/drugs/ivonescimab--egfr-mutated-non-small-cell-lung-cancer/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/ivonescimab--egfr-mutated-non-small-cell-lung-cancer/terms-and-abbreviations.md)
- [Ivonescimab: EGFR-mutated non-small-cell lung cancer](https://www.evicenter.com/drugs/ivonescimab--egfr-mutated-non-small-cell-lung-cancer/executive-summary) · [Markdown](https://www.evicenter.com/drugs/ivonescimab--egfr-mutated-non-small-cell-lung-cancer/executive-summary.md)
- [Ivonescimab in EGFR-mutated non-small-cell lung cancer: Product information and disease description](https://www.evicenter.com/drugs/ivonescimab--egfr-mutated-non-small-cell-lung-cancer/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/ivonescimab--egfr-mutated-non-small-cell-lung-cancer/product-information-and-disease-description.md)
- [Ivonescimab in EGFR-mutated non-small-cell lung cancer: Clinical evidence](https://www.evicenter.com/drugs/ivonescimab--egfr-mutated-non-small-cell-lung-cancer/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/ivonescimab--egfr-mutated-non-small-cell-lung-cancer/clinical-evidence.md)
- [Ivonescimab in EGFR-mutated non-small-cell lung cancer: Economic information and modeling report](https://www.evicenter.com/drugs/ivonescimab--egfr-mutated-non-small-cell-lung-cancer/economics) · [Markdown](https://www.evicenter.com/drugs/ivonescimab--egfr-mutated-non-small-cell-lung-cancer/economics.md)
- [Ivonescimab in EGFR-mutated non-small-cell lung cancer: prevalence by geography](https://www.evicenter.com/drugs/ivonescimab--egfr-mutated-non-small-cell-lung-cancer/prevalence) · [Markdown](https://www.evicenter.com/drugs/ivonescimab--egfr-mutated-non-small-cell-lung-cancer/prevalence.md)
- [Ivonescimab in EGFR-mutated non-small-cell lung cancer: cost-effectiveness analyses and utility weights](https://www.evicenter.com/drugs/ivonescimab--egfr-mutated-non-small-cell-lung-cancer/cost-effectiveness-analyses) · [Markdown](https://www.evicenter.com/drugs/ivonescimab--egfr-mutated-non-small-cell-lung-cancer/cost-effectiveness-analyses.md)
